
Unique therapeutic options matched to patient characteristics identified by real-world evidence (RWE)
03 June 2020
- Interest and use of RWE in the pharmaceutical industry is expected to increase in the coming year, due to its role in regulatory approvals
- However, studies have shown that accuracy levels of electronic data can vary from as low as 30% to as high as 90%
- Where data is inaccurate, data enrichment will be required
- Pharmaceutical companies will continue to design observational studies to reinforce efficacy arguments
Click here to learn more
About SVMPharma
SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.
For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com
ref: APR2020BR001